Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
How to buy Kiniksa Pharmaceuticals stock | $13.63
Learn how to easily invest in Kiniksa Pharmaceuticals stock.
Kiniksa Pharmaceuticals, Ltd is a biotechnology business based in the US. Kiniksa Pharmaceuticals shares (KNSA) are listed on the NASDAQ and all prices are listed in US Dollars. Kiniksa Pharmaceuticals employs 168 staff and has a market cap (total outstanding shares value) of 0.00.
How to buy shares in Kiniksa Pharmaceuticals
- Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – KNSA – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Kiniksa Pharmaceuticals stock price (NASDAQ: KNSA)Use our graph to track the performance of KNSA stocks over time.
Kiniksa Pharmaceuticals shares at a glance
|Latest market close||$13.63|
|52-week range||$13.00 - $24.70|
|50-day moving average||$14.34|
|200-day moving average||$17.24|
|Wall St. target price||$32.00|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-3.34|
Buy Kiniksa Pharmaceuticals shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Kiniksa Pharmaceuticals stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Kiniksa Pharmaceuticals price performance over time
|1 week (2021-07-22)||N/A|
|1 month (2021-07-02)||-3.20%|
|3 months (2021-04-30)||-17.19%|
|6 months (2021-01-29)||N/A|
|1 year (2020-07-29)||N/A|
|2 years (2019-07-29)||N/A|
|3 years (2018-07-29)||N/A|
|5 years (2016-07-29)||N/A|
Kiniksa Pharmaceuticals financials
|Gross profit TTM||$0|
|Return on assets TTM||-41.24%|
|Return on equity TTM||-77.41%|
|Market capitalisation||$1 billion|
TTM: trailing 12 months
Shorting Kiniksa Pharmaceuticals shares
There are currently 4.8 million Kiniksa Pharmaceuticals shares held short by investors – that's known as Kiniksa Pharmaceuticals's "short interest". This figure is 2.3% up from 4.7 million last month.
There are a few different ways that this level of interest in shorting Kiniksa Pharmaceuticals shares can be evaluated.
Kiniksa Pharmaceuticals's "short interest ratio" (SIR)
Kiniksa Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Kiniksa Pharmaceuticals shares currently shorted divided by the average quantity of Kiniksa Pharmaceuticals shares traded daily (recently around 417596.15720524). Kiniksa Pharmaceuticals's SIR currently stands at 11.45. In other words for every 100,000 Kiniksa Pharmaceuticals shares traded daily on the market, roughly 11450 shares are currently held short.
However Kiniksa Pharmaceuticals's short interest can also be evaluated against the total number of Kiniksa Pharmaceuticals shares, or, against the total number of tradable Kiniksa Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Kiniksa Pharmaceuticals's short interest could be expressed as 0.07% of the outstanding shares (for every 100,000 Kiniksa Pharmaceuticals shares in existence, roughly 70 shares are currently held short) or 0.1793% of the tradable shares (for every 100,000 tradable Kiniksa Pharmaceuticals shares, roughly 179 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Kiniksa Pharmaceuticals.
Find out more about how you can short Kiniksa Pharmaceuticals stock.
Kiniksa Pharmaceuticals share dividends
We're not expecting Kiniksa Pharmaceuticals to pay a dividend over the next 12 months.
Kiniksa Pharmaceuticals share price volatility
Over the last 12 months, Kiniksa Pharmaceuticals's shares have ranged in value from as little as $13 up to $24.7. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Kiniksa Pharmaceuticals's is -0.0736. This would suggest that Kiniksa Pharmaceuticals's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Kiniksa Pharmaceuticals has bucked the trend.
Kiniksa Pharmaceuticals overview
Kiniksa Pharmaceuticals, Ltd. , a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need worldwide. Its product candidates include Rilonacept, which is in Phase III clinical trials for the treatment of recurrent pericarditis, an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody that is in Phase II clinical trials for the treatment of giant cell arteritis; and Vixarelimab, a monoclonal antibody, which is in Phase 2a clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition. The company's preclinical product candidates comprise KPL-404, a monoclonal antibody inhibitor of the CD40/CD40L interaction, a central control node of T-cell-dependent, and B-cell-mediated humoral adaptive immunity. The company has a clinical collaboration with Kite Pharma, Inc. to evaluate the combination of Yescarta and Mavrilimumab in patients with relapsed or refractory Large B-Cell lymphoma. Kiniksa Pharmaceuticals, Ltd.
Kiniksa Pharmaceuticals in the news
Hedge Funds Aren’t Crazy About Kiniksa Pharmaceuticals, Ltd. (KNSA) Anymore
Kiniksa Pharmaceuticals to Report Second Quarter 2021 Financial Results on August 3, 2021
Kiniksa Pharmaceuticals to Report Second Quarter 2021 Financial Results on August 3, 2021
Frequently asked questionsWhat percentage of Kiniksa Pharmaceuticals is owned by insiders or institutions?
Currently 4.394% of Kiniksa Pharmaceuticals shares are held by insiders and 92.476% by institutions. How many people work for Kiniksa Pharmaceuticals?
Latest data suggests 168 work at Kiniksa Pharmaceuticals. When does the fiscal year end for Kiniksa Pharmaceuticals?
Kiniksa Pharmaceuticals's fiscal year ends in December. Where is Kiniksa Pharmaceuticals based?
Kiniksa Pharmaceuticals's address is: Clarendon House, Hamilton, Bermuda, HM 11 What is Kiniksa Pharmaceuticals's ISIN number?
Kiniksa Pharmaceuticals's international securities identification number is: BMG5269C1010 What is Kiniksa Pharmaceuticals's CUSIP number?
Kiniksa Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: G5269C101
More guides on Finder
How to buy Argus Capital Corp (ARGU) stock when it goes public
Everything we know about the Argus Capital Corp IPO, plus information on how to buy in.
How to buy RenovoRx (RNXT) stock when it goes public
Everything we know about the RenovoRx IPO, plus information on how to buy in.
How to buy Draganfly (DPRO) stock when it goes public
Everything we know about the Draganfly IPO, plus information on how to buy in.
How to buy Society Pass Incorporated (SOPA) stock when it goes public
Everything we know about the Society Pass Incorporated IPO, plus information on how to buy in.
How to buy Guardforce AI Co (GFAI) stock when it goes public
Everything we know about the Guardforce AI Co IPO, plus information on how to buy in.
How to buy IsoPlexis Corporation (ISO) stock when it goes public
Everything we know about the IsoPlexis Corporation IPO, plus information on how to buy in.
How to buy Marpai (MRAI) stock when it goes public
Everything we know about the Marpai IPO, plus information on how to buy in.
How to buy DoubleDown Interactive (DDI) stock when it goes public
Everything we know about the DoubleDown Interactive IPO, plus information on how to buy in.
How to buy Omniq Corp (OMQS) stock when it goes public
Everything we know about the Omniq Corp IPO, plus information on how to buy in.
How to buy Mechanical Technology (MKTYP) stock when it goes public
Everything we know about the Mechanical Technology IPO, plus information on how to buy in.
Ask an Expert